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Abstract
The Rotational Orientation of the T Cell Receptor With Respect to Its
PeptideiMHC Ligand
Sangwook Tim Yoon 
Yale University 
1995
The T cell receptor (TCR) is the multi-chained cell surface molecule that 
mediates the specific recognition of antigen by the T cell. The a  and p chains of 
the TCR are members of the immunoglobulin gene superfamily and form the 
antigen binding components of the TCR. Although the function of ap-TCRs has 
been well characterized, less is known about their molecular structure. Current 
three-dimensional structural models of TCR are based on the similarities in 
primary sequence between the TCR with immunoglobulin genes. Models of the 
ternary structure of the TCR and MHC complex have also been proposed.
These models, however, do not address the question of the rotational orientation 
of TCR on the peptide:MHC complex. This thesis uses molecular biological 
techniques to characterize the molecular interactions between TCR and the 
peptide:MHC complex to determine the rotational orientation of TCR bound to 
the peptide:MHC complex.
The well characterized CD4+ l-Ak restricted cloned T cell line, D10, and its 
specific ligands are used in T-cell functional response assays to identify 
TCR:ligand interaction sites. An analysis of the antigenic peptide by truncation 
and substitution of residues identify the residue in position p2 as important for 
interaction with TCR. Studies with MHC molecules containing mutations at
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various putative TCR or peptide interaction sites identify residues in MHC a- 
chain HVR2 as an important TCR interaction site. Finally, residue 52 of the TCR 
a-chain CDR2 is mapped to peptide position p2 and MHC a-chain HVR2. These 
data are synthesized into a three-dimension ternary model of interaction between 
TCR, antigenic-peptide, and MHC using a computer graphics program. These 
results demonstrate a direct interaction between the germline encoded CDR2 of 
the TCR with the antigenic-peptide, which provides an explanation for why 
certain Va genes are highly correlated with certain peptide-antigens and 
suggests that TCR-MHC spatial interaction have stereotypic rotational 
orientation.
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Chapter 1
Introduction
General Function of The a(3 T Celt Receptor
The T  cell receptor (TCR) is a complex of distinct polypeptide chains used 
by T ceils to transduce a signal into the cell upon binding a specific ligand. The 
a and p chains of the TCR form its antigen-binding domain and are highly 
polymorphic polypeptides encoded by transcription units produced by DNA 
recombination events that occur in individual somatic cells. The clonal 
distribution of independently recombined a and p chains provides the immune 
system with a great diversity of receptors which enables the T cell system to 
recognize an enormous variety of antigens. T  cell receptors recognize short 
polypeptides bound to self class I or class II major histocompatibility complex 
(MHC) molecules: This is called self-MHC restricted peptide recognition. TCRs 
can also recognize non-self MHC molecules without the addition of foreign 
peptide (allo-recognition).
The developmental course of T cells in the thymus is determined by their 
TCR specificities. Developing T cells with TCRs that are self-restricted are 
positively selected, and those with TCRs that are self-reactive are negatively 
selected. These selection events lead to the export from the thymus and into the 
peripheral lymphoid system of mature T cells that are self MHC restricted and 
self tolerant. In the periphery, T cells have a variety of functions including direct 
cytotoxic activity (Killer T-cells), antibody production (B-cells), and T-cell 
regulation (Helper T-cells).
10
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Although a great deal is known about the function of ap-TCRs, much less 
is known about the how the TCR interacts with its ligands to produce activation 
of T  cells. In light of the recently mounting evidence that TCR.Iigand interactions 
are more complex than simple on/off switches, the understanding of the 
molecular details of TCR interaction with its ligand has become increasingly 
important. The study of the spatial interaction sites between TCR and 
peptide:MHC is the focus of this thesis.
One possible approach in studying the interaction between TCR and 
ligand is to co-crystallize both molecules bound to each other and to use X-ray 
diffraction analysis to precisely determine their structural interactions. This has 
not been feasible and probably will not be accomplished for some time into the 
future because of the difficulty in producing the necessary TCRiligand crystal. 
Another approach is to determine the structure of each of the components and to 
identify interaction sites by less direct means. This latter approach is taken in 
this thesis.
MHC Structure
In any attempt to study the interaction between TCR and ligand, some 
information about the structures of the individual molecules is a prerequisite. In 
this regard, detailed information is available only for MHC molecules. Because 
the T cell system in this thesis is a CD4+ la restricted, the MHC class II molecule 
is discussed. The MHC class II molecule (or la antigen for mice) is a 
heterodimeric cell-surface glycoprotein consisting of one heavy (33-34kDa) chain 
(a) and one light (28-29kDa) chain (P) which are noncovalently associated and 
span the plasma membrane (Glimcher and Griffith 1987). There are two 
isotypes of la molecules, the l-A molecule and the l-E molecule. The l-A
11
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molecule Is composed of heterodimers of Aa and Ap chains, and the l-E 
molecule is composed of heterodimers of Ea and Ep chains. Each of these 
polypeptides has two extracellular domains (approximately 96 amino-acids long), 
a transmembrane region, and a short intracytoplasmic tail.
The structural organization of the la genes has been previously 
characterized. The first exon codes for a signal peptide that also includes the 
first 3-6 amino-acids of the first extracellular domain. The second and third 
exons encode the a1/p1 domains and a2/p2 domain, respectively. The 
remaining exons, which differ slightly for a and p chains, encode the 
transmembrane region, cytoplasmic tail, and the 3' untranslated region. Many 
alleles of la genes have been sequenced, and areas of allelic hypervariability 
have been identified to reside mostly in the second exon which encodes for a1 
and pi domain (Estess, Begovich etal. 1986; Glimcher and Griffith 1987; Klein, 
Satta et al. 1993). Three hypervariable regions (HVRs) have been identified. 
HVR1 residues are closest to the N-terminus and are found in the p-sheets and 
thus do not directly interact with TCR. HVR2 and HVR3 residues are found on 
the a-helix and can interact with either peptide or MHC. In contrast, the a2 and 
P2 domains are much less polymorphic and do not contain distinct regions of 
allelic hypervariability. This may reflect the need to maintain a conserved 
structure so that nonpolymorphic molecules can interact with these domains, 
such as CD4, which has been shown to bind a site on the P2 domain(Lombardi, 
Barber et al. 1991; Cammarota, Scheme et al. 1992; Konig, Huang et al. 1992).
X-ray crystallographic determination of MHC structures has provided 
detailed information about the nature of ligands recognized and distinguished by 
TCRs. This has been very helpful in studying how TCRs might interact with the 
MHC class II molecule. The membrane proximal domains (a2 and p2) form
12
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immunoglobulin folds that interact with each other in an unusual angle and form 
a platform for the rest of the molecule(Davies and Padlan 1990). Each of the N- 
terminal membrane-distal domains (a1 and p1) form four anti-parallel (3-sheets 
and a long a-helix, which, when paired with the analogous structures of its 
heterodimeric partner, forms a peptide binding groove (Figure 1 )(B]orkman, 
Saper et al. 1987; Brown, Jardetzky et al. 1993; Jardetzky, Brown et al. 1994). 
The antigenic peptide binds the MHC groove in an extended conformation with 
portions of the peptide clearly out of the groove and available for interaction with 
TCR and with other portions deep in the groove and unavailable for direct 
interaction with TCR. Analysis of the polymorphic MHC residues indicates that 
many are positioned to interact with the peptide and that others are positioned to 
interact with the TCR. This validates a number of experiments which identified 
residues on the MHC a-helices which point towards the TCR (away from the 
APC cell membrane).
13
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Figure 1: The structure of MHC class II molecule
The membrane distal domains that form the peptide binding groove are 
shown in this schematic diagram of the HLA-DR1 molecule (adapted from Brown 
et al. 1993). The two a-helices are above the p-sheets and the a-chain helix is 
at the top of the page.
14
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TCR Structure
In comparison to the MHC molecules, considerably less detail is known 
about TCR structure. One major reason is that unlike MHC, the crystal structure 
of a TCR has not yet been determined. Nevertheless, useful information has 
been deduced from TCR primary structure and genetic organization. TCR a and 
P chains closely resemble that of immunoglobulin heavy and light chains; the 
structure of which is well known (Acuto, Hussey et al. 1983; Kappler, Kubo et al. 
1983; Kaye, Porcelli etal. 1983; Chien, Gascoigne etal. 1984; Hedrick, Cohen 
et al. 1984; Hedrick, Nielsen et al. 1984; Patten, Yokota et a l.; Saito, Kranz et al. 
1984; Staerz, Pasternack et al. 1984; Clevers, Alarcon et al. 1988). TCR genes 
are similar to antibody genes in genomic organization, consisting of separate 
V(D)J gene segments which somatically recombine to produce an intact exon 
encoding the TCR variable domain. The TCR a-chain, like the Ig light-chain, is 
formed by recombination of V and J gene segments, while the TCR p-chain, like 
the Ig heavy-chain, is formed by a recombination between V, D, and J gene 
segments. TCR genes are different from Ig genes in that they have fewer V  
gene segments and more J gene segments (Table 1). TCRs have ~100 Va and 
25 Vp gene segments versus Ig’s 250 V k  and 250-1000 VH gene segments. In 
contrast, there are 50 Ja and 12 jp  gene segments as compared to 4 Jk and 4 
JH gene segments for lg’s(Davis and Bjorkman 1988).
16
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Table 1 The number of gene segments in T cell receptors and Immunoglobulins
Immunoglobulin TCR a:(3 TCR y:5
Gene Segment H k  a (3 y 5
V 250- 250 100 25 7 10
1000
D 10 0 0 2 0 2
J 4 4 50 12 2 2
17
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The TCR and Ig genes also share homology in their amino-acid 
sequence, prompting several workers(Chothia, Boswell et al. 1988; Davis and 
Bjorkman 1988; Claverie, Prochnicka-Chalufour et al. 1989) to propose that the 
TCR forms immunoglobulin folds like antibodies. Such model building is 
complicated by the large variation in the sequence of T cell receptors, which 
results in residue identity of some TCR pairs of only 15%. Furthermore there is 
relatively low homology between TCR and immunoglobulins, typically 25% 
identity in the V  domain(Chothia, Boswell et al. 1988). Nevertheless, other 
members of the Ig gene superfamily as diverse as CD4, CD8, and CD2 have 
been demonstrated to have similar a fold when analyzed by X-ray 
crystallography, suggesting that modeling the TCR in this manner is correct. 
Further, despite the overall low sequence identity, there is much higher 
sequence identity at residues identified to be important for the framework 
structure of antibodies(Chothia, Boswell et al. 1988).
In these models, the regions of TCR sequence hypervariability fall roughly 
on areas analogous to the immunoglobulin complementarity determining regions 
(CDRs) which are variable loops connecting the p sheets of the Ig framework 
and form the antigen combining site on antibodies. Like immunoglobulin, TCR 
CDR1 s and CDR2s are found entirely within those parts of the variable domain 
encoded in the V gene segments, while CDR3s are found within areas 
generated by the V(D)J recombination. The structures of the TCR CDR1s and 
CDR2s are probably significantly different from immunoglobulin CDRs because 
TCR CDRs do not fit the sequence motifs of the canonical antibody CDR 
structure(Tramontano, Chothia et al. 1990; Chothia, Lesk et al. 1992). This 
makes it difficult to predict TCR CDR structure with any detail. However, if TCRs 
indeed fold like antibodies, the TCR CDR loops must arise from similar regions of
18
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the framework structure and occupy generally the same regions relative to each 
other as antibody CDR loops. Thus, TCR CDR1 and CDR2 loops must be 
located more peripherally and the CDR3 loops more centrally.
These CDR loops form a highly diverse solvent exposed surface at the 
membrane distal portion of the TCR thought to be the antigen binding surface of 
the molecule. Since the diversity of TCR specificity must be a reflection of the 
structural variation of the CDR loops, it is believed that the TCR CDR loops form 
the antigen binding site, in a position analogous to those of antibody CDR loops. 
Consistent with this, many studies point to the TCR CDRs as controlling TCR 
specificity(Acha-Orbea, Mitchell et al. 1988; Engle and Hedrick 1988; Hedrick, 
Engel et a l . , 1988; Danska, Livingstone et al. 1990; Lai, Jang et al. 1990; Sorger 
and Hedrick 1990; Nalefski, Kasibhatla et al. 1992).
TCR Ligand Interaction Models
Based on the above model of TCR structure and the known structure of 
MHC molecules, several workers have proposed that during TCRrMHC 
interaction the relatively less diverse CDR1s and CDR2s are in contact with the 
relatively less polymorphic MHC a-helices and that the more diverse CDR3s are 
in contact with the MHC bound peptide, which is potentially much more diverse 
in sequence than the MHC a-helices. Clearly, the central location of the CDR3s 
would place them in an ideal position to interact with the antigenic 
peptide(Chothia, Boswell et al. 1988; Davis and Bjorkman 1988; Claverie, 
Prochnicka-Chalufour et al. 1989).
Earlier data supporting this model consist mainly of correlations between 
TCR sequence and specificity and of loss of recognition mutations of CDR loop 
or MHC helix (Fink 1986, Engle 1988, Danska 1990, Eckels, 1990, and
19
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Deilabona 1991). Although these data Identity regions on either TCR or MHC 
which are important in TCR MHC interaction, they do not provide information 
about intermolecular contact during a physiological TCRrligand interaction. More 
recently, data supporting CDR3 interaction with peptide has been produced with 
mice transgenic for either the a  or p chain of a TCR specific for a cyt-c peptide 
(Jorgensen 1992). A strong charge change correlation is found between CDR3 
residues of the non-transgenic chains and the ability to recognize charge change 
variants of the cyt-c peptide, suggesting an ionic interaction between CDR3 and 
the peptide. These studies, however, do not address TCR:MHC interaction sites 
nor the rotational orientation of the TCR with respect to MHC.
The question of the rotational orientation of the TCR is partially answered 
in an earlier study published by our laboratory, in which a change of 7 amino- 
acids on the amino-terminal half of TCR a-chain altered recognition of the MHC 
a-chain HVR2 (Hong 1992). These data provide the best delineation of 
interaction sites between TCR and ligand, however, these data suffer from 
several limitations. Because whole regions of TCR and MHC are involved, only 
broad statements about TCR:MHC orientations can be made. Changing large 
numbers of residues raises the likelihood of unexpected conformational changes. 
Hong’s study involves recognition of allogeneic-MHC molecules without the 
deliberate addition of peptide, leaving open the possibility that different peptide 
binding repertoires of the variant MHC molecules might produce different T cell 
response patterns which may confound the interpretation of the data. This thesis 
address these limitations by using TCRiligand mutations involving single amino- 
acid residues. Furthermore, TCR interaction with MHC given a known specific 
peptide is studied to determine whether TCR:ligand orientation during peptide 
specific interaction is similar to that of allo-reactive interaction.
20
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D10 T Cell Model System
The Janeway laboratory has been studying TCRiligand interactions with a 
Th2 cloned cell line, D10.G4.1 (D10) which recognizes a peptide of conalbumin 
(CA) restricted by l-Ak and also recognizes several allogenic l-A molecules (I- 
b^,v,p,q. and dj j^ e conalbumin-specific recognition and alloreactive recognition 
are mediated by a single TCR, as indicated by inhibition with anti-D10 TCR 
clonotypic antibodies (Kaye and Janeway 1984; Janeway, Dianzani et al. 1989) 
and by gene transfection experiments (Hong, Chelouche et al. 1992). When 
D10 TCR a  and p genes and the CD4 gene are co-transfected into the TCR a'P' 
CD4‘8' hybridoma, 4G4, the resulting TCR transfectant (D10/D10) gains the 
same TCR specificity as the donor T cell clone (Hong et al. 1992). This allows 
examination of TCR specificity changes resulting from TCR sequence changes 
by transfecting mutated D10 TCR genes into the 4G4 cell line.
Using the D10 T cell clone or D10-related TCR transfectants, this thesis 
addresses several issues regarding TCRiligand interactions. First, the antigenic 
peptide which D10 recognizes is characterized in greater detail. The objective is 
to determine a minimal peptide that D10 will recognize and to identify peptide 
residues that are involved in direct TCR contact. These data are helpful in 
interpreting the results from later experiments. Second, TCRiligand interaction 
sites are investigated with wildtype and mutant TCR transfectants, modified 
conalbumin peptides, and a panel of MHC transfected fibroblast cell lines.
These studies provide strong evidence that TCR a-chain CDR1 and CDR2 are 
involved in interactions with the N-terminus of the conalbumin peptide, MHC p- 
chain helix, and MHC a-chain helix all at the same time. Analysis of TCR 
transfectants containing single amino-acid changes indicates that position 51 of 
TCR a-chain (CDR2) is involved in peptide contact. Based on these data a
21
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computer model of the TCR molecule oriented on the MHC molecule is 
developed.
22




The mice used in these studies were obtained from the Jackson 
Laboratory (Bar Harbor, ME) or from the Core Mouse Breeding Facility 
maintained at Yale. The following mouse strains were used: B10.BR (l-Ak), 
B10.S (7R) (l-As), B10.P 73NS (l-Au), BALB/c (l-Ad), B10.D2 (l-Ad), B10.R III (I- 
Ar), B10.M/SN (l-Af), SM/J (l-Au), B10.G (l-Aq), and C57BL76J (l-Ab).
Peptides
Peptides were synthesized by either of three methods, the RAMPS 
peptide synthesizer, ABI automated synthesizer, or by the peptide core facility at 
Yale Medical School. All methods used Wang Resins and FMOC chemistry. 
Peptides CA1-36, used in the early screening experiments, were synthesized on 
the RAMPS synthesizer in Wang Resin Cartridges from DuPont using FMOC 
chemistry. After the last amino acid was coupled, the protecting group was 
removed, the peptide cleaved from the resin, washed extensively in ether, and 
dried in a vacuum-centrifuge (SpeedVac) overnight. Some of these peptides 
were later analyzed on HPLC and shown to be of good quality. Peptides CA1, 
CA2, CA3, CA36, and CA37 were also synthesized by the peptide core facility at 
Yale Medical School using an Applied Biosystems machine. These peptides 
were purified by HPLC and analyzed by mass spectroscopy to insure the quality 
of the peptides. Finally, peptides CA50, CA62-CA73 were synthesized on the 
automated peptide synthesizer. These peptides were analyzed by HPLC and
23
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shown to be of better than 90-95% purity and thus were used without further 
purification.
Antibodies
The following monoclonal antibodies were used: anti-TCR clonotypic 
antibodies 3D3, 5A, and 4B (Kaye et al., 1983; Rojo and Janeway, 1988); anti- 
V|38 F23.2 (Staerz et al., 1985); anti-CD3e 145-2C11 (Leo et al., 1987); anti-CD4 
GK1.5 (Dialynas et al., 1983); anti-LFA-1 M17/5.2 (Sanchez-Madrid et al., 1982); 
anti-CD45; anti-K/D Y3; and anti-Ly6. Antibodies were purified by affinity 
chromatography over staphylococcal protein-A columns by the hybridoma core 
facility in the section of immunobiology. Supernatants from antibody secreting 
hybridomas were provided by the hybridoma facility and used as indicated in the 
results section.
Growth and Maintenance of Cloned T cells
The cloned CD4+ Th2 T-cell lines D10.G4.1 (Kaye, Porcelli et al. 1983) 
and AK8 (Rojo, Kemer et al. 1989) have been described previously. Both T-cell 
lines are specific for a peptide of hen egg conalbumin in the context of I-Ak. 
Briefly, these cells were maintained with weekly feedings of Click’s EHAA media 
with 5% FCS between antigen stimulation. They were stimulated every 3-4 
weeks with 100ug/ml of hen egg conalbumin (Sigma C-0755 Type I) and 
mitomycin C-treated spleen cells (5x105/ml) from B10.BR mice in Click’s EHAA 
media supplemented with 5% (v/v) heat inactivated FCS and IL-2 (1 U/ml).
T cell clone peptide stimulation assays
In all assays, T cells were rested for more than 7 days after their last 
stimulation with antigen and spleen cells. These cells were centrifuged over
24
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
lymphocyte separation media, then the viable cells at the interface were washed 
at least twice in culture media before use. Experiments were earned out in flat 
bottom 96 well plates using 1-2x10^ T  cells. T cell assays were allowed to 
proceed in a 37°C incubator at 5% C 02 for approximately 68 hours, before 
pulsing with 3H-thymidine for 4 hours. These cells were then harvested on a 
Skatron cell harvester and the incorporated radioactivity measured on a 
scintillation beta counter. B10.BR spleen cells were treated with mitomycin-c 
and used at approximately 2-3x105 per well.
cDNA Construction
The D10 cDNA were previously cloned and inserted into expression 
vectors(Hong, Chelouche et al. 1992). Briefly, the D10 a-chain was cloned by 
screening a cDNA library with a Va probe and then ligating into the pENeoMos 
expression vector, which contains the neomycin resistance gene and an SV40 
viral promoter(Hong, Chelouche et al. 1992). New D10 a-chain cDNAs used in 
this thesis were generated by the overlap PCR method(Horton, Hunt et al. 1989). 
cDNAs with desired mutated sequences were generated by PCR amplification of 
the wildtype D10 a-chain template with internal primers containing the 
appropriate base-pair changes. These PCR products were cut with EcoRV and 
Pstl enzymes into an approximately 500bp fragment and subcloned into a 
similarly cut intermediary bluescript vector containing the D10 a-chain cDNA. 
Then, a Sacl and BamHI fragment of the intermediary construct was ligated back 
into the pENeoMos D10 cDNA. The final construct was then sequenced in the 
~500bp region produced by PCR amplification. This was important because 
fairly high mutation rates were found with the overlap PCR method.
25
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D10 (3-chain was previously cloned by PCR and inserted into the EcoRI 
site in the pSRa expression plasmid which does not contain the neomycin 
resistance gene. The CD4 expression plasmid, which also does not contain the 
neomycin resistance gene, was provided by Dan Littman (UCSF).
TCR and CD4 Transfection
2x106 4G4 cells were seeded into 50ml of media containing 10% FCS and 
incubated in a T75 flask. After 2 days, 1-1.5x107 cells per flask were collected, 
washed twice, and resuspended at 1.5x107/0.8ml in PBS with 10mM MgCI2. 
Approximately 40pg of each DNA plasmid were added to the cells in a volume 
less than 100pl and incubated at room temperature (RT) for 9min, then on ice for 
1min. After transferring the cells to cuvettes, the cells were electroporated on 
the BioRad GenePulser at 960pF and 320volts and placed immediately on ice 
for 10min. The cells were transferred to T75 flasks, 5ml of FCS free media 
added, and incubated at RT for 20min. 40ml of media with 10% FCS were 
added and the cells were transferred to a 37°C air incubator containing 5% C02 
atmosphere. After two days, the cells were transferred to 96 well flat bottom 
plates in media containing 1 mg/ml of G418. After 10 days the wells containing 
surviving cells were expanded in 24well plates and screened by antibody 
staining. Early screening and subcloning produced the best results.
TCR Transfectant Stimulation Assays
The exact conditions of TCR transfectant stimulation assays differed from 
experiment to experiment. In general, experiments were carried out on 96 well 
flat-bottom plates with 30,000-50,000 TCR transfectants per well. When spleen 
cells were used as APCs, approximately 200,000-300,000 cells per well were 
used. When fibroblast lines were used as APCs, approximately 30,000-50,000
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cells per well were used. These conditions produced the most optimal 
stimulation without increasing non-specific IL-2 secretion. The TCR 
transfectants were incubated for 16-18 hours, freeze thawed, and the IL2 content 
measured by a CTLL assay.
CTLL-2 Stimulation Assays
All IL-2 assays were performed on 96 well flat bottom plates with CTLL-2 
responder cells. 50pl per well of supernatant from experimental plates were 
transferred to a clean plate, frozen in the -70C freezer or liquid nitrogen freezer, 
and thawed to kill any viable cells. Approximately 5,000-10,000 CTLL cells/well 
were added (50pl) and allowed to proliferate for 16hrs, pulsed with high specific 
activity 3H-thymidine (1 pCi/well) for four hours, and harvested onto filter mats.
The incorporated radioactivity was counted on a p-scintillation counter. At times, 
the 3H-thymidine pulsed cells were frozen and thawed before harvest.
MHC Expressing Fibroblast and Lymphoblastoid Cell Lines
L-cell transfections were done by Ca2P 04 precipitation method. Briefly, 
DNA was linearized with restriction enzyme, phenol extracted, ethanol 
precipitated, and washed in 70% ethanol. The DNA was then resuspended in 
450pl of 2.5M CaCI2 and added dropwise with agitation into 500pl of 2X HBSS. 
This was incubated for 30min at room temperature (RT) before adding to 2x106 
L-cells in 10mm plate and incubated 16hrs at 37C. The cells were washed twice 
with 1xPBS and fresh media added. After an overnight incubation the G418 
selection media was added.
The N-series cell lines are fibroblasts obtained from Ned Braunstein.
These cells bear l-A molecules with exon or hemi-exon shuffle between b, d, or k
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alleles and are described in the results section. The T  series cell lines are 
lymphoblastoid cell derivatives of M12 obtained from David McKean. These 
cells bear l-Ak molecules with mutations in either a1 or 01 domains to l-Ad allele 
sequences.
Immunization and Cloning of T Cells
Approximately 30-50pg of peptide was dissolved in 2X PBS and mixed in 
equal volumes with complete Freund’s adjuvant. The mixture was well 
emulsified by sonication and injected into the mouse hind footpads. After 7-9 
days the lymph nodes were dissected and the cellular components freed from 
the lymph node with glass slides. Some of the cells were tested for proliferation 
to the immunizing peptide and the remaining cells were cultured in bulk with 
peptide for 2-3 days until activated cells were visible. The T cells were harvested 
and washed in FCS free media and mixed with an equal number of BW cells, 
which were also washed in FCS free media. This mixture of cells was pelleted 
together and 50% PEG added. The cells were gently mixed for 1min and diluted 
with dropwise addition of 10ml FCS free pre-warmed media. The cells were 
pelleted, washed, and resuspended in media containing 10% FCS and HAT. 
They were plated on 96 well plates at 6x104 cells per well, and 7-10 days later 
the media was changed to HT containing media. The surviving cells were then 
screened for reactivity to peptide.
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Chapter 3
Characterizing D10’s Antigenic Peptide
Each component of the TCRrligand complex influences the affinity and 
effectiveness of the complex in transducing a signal to the T-cell. Each of the 
three key components of the complex (peptide, MHC, and TCR) is manipulated 
in this theses to investigate which residues are important in altering T-cell 
responses. Between the three components of the complex, the peptide is 
perhaps the most easy to manipulate experimentally. Determination of the 
antigenic-peptide for D10 TCR and characterization of the peptide residues 
important in TCR interaction is an important step in determining contact sites 
between TCR and ligand.
Although it was known very early on that the l-Ak- restricted D10 T cell 
clone recognizes chicken egg conalbumin protein, the specific antigenic peptide 
was not known. More precise information was determined by Nakagawa and co­
workers (Nakagawa, Von Grafenstein et al. 1991). They used PCR to subclone 
fragments of the conalbumin cDNA into protein expression vectors and identified 
the general region of conalbumin which contained the antigenic peptide. They 
then synthesized overlapping peptide fragments of this region based on the 
sequence of a published cDNA of conalbumin(Williams, Elleman et al. 1982). 
They used these peptides in D10 stimulation assays and identified a 13mer 
peptide (HWGAIEWEGIESG) corresponding to conalbumin residues 134-146 as 
the stimulatory peptide.
During the course of this thesis, it was discovered that there was a 
sequencing error (or perhaps a natural allelic polymorphism) at conalbumin 
position 135 in the Williams paper. The natural residue is actually an arginine 
instead of tryptophan, such that the actual antigenic peptide is
29
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HRGAIEWEGiESG. Thus, the incorrect peptide was the basis of the first series 
of peptides synthesized. Later experiments with variants of the true wildtype 
peptide were, nevertheless, consistent with data from the earlier data.
Analysis of D10 Responses to Peptides With Single Amino-Acid 
Substitutions in the 13mer Peptide HWGAIEWEGIESG
Variants of HWGAIEWEGIESG peptide containing single residue 
substitutions were synthesized in order to analyze D10 TCR specificity and to 
develop analog peptides which can antagonize D10 T cell stimulation with 
wildtype peptide. Such dominant antagonist peptides were initially described by 
De Magistris et al(De Magistris, Di Tommaso et al. 1992). In order to 
accommodate this second goal, analog peptides with conservative as well as 
less conservative substitutions at single residues were synthesized. Figure 2 
shows the results of D10 proliferation assays with these analog peptides. 
Interestingly, the HWGAIEWEGIESG peptide (CA1) is not the best stimulator of 
D10, with the peptide containing the non-conservative substitution of tryptophan 
to histidine at position p2 (CA2) or the relatively more subtle substitution of 
glycine to alanine at position p9 (CA16) stimulating significantly better. On the 
other hand, some of the other peptides are much less capable of stimulating 
D10, such as the peptide CA8, which has an extremely conservative amino-acid 
substitution, isoleucine to leucine. The residues in which substitutions have 
significant negative or positive influence on D10 responses are confined to 
position p2 and positions p4-p9. Peptides with substitutions closer to the C- 
terminus have relatively minor effects on D10 stimulation. This suggests that 
there are no critical or finely discriminating TCR or MHC contact residues after 
position p9. Although theoretically a combination of both TCR and MHC 
changes which counterbalance each other may account for this finding, it seems
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a less likely explanation. As will be seen later, similar data are produced with 
analog peptides of the true antigenic peptide.
31
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Figure 2: D10 T cell responses to variant peptide-antigens in the context of l-Ak
Resting D10 T cells were stimulated with three doses of peptide variants 
of CA1 (HWGAIEWEGIESG) in the presence of B10.BR (!-Ak) spleen cells. The 
cultures were incubated for 68 hours and pulsed with 3H-thymidine for four hours 
and the incorporated radioactivity quantitated in a p-scintillation counter. The 
response to the highest dose (50pg/ml) is shown.
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The response pattern to the tryptophan-containing variant peptides were 
tested on the D10 TCR transfectant (D10/D10) and two TCR transfectants 
containing mutations in the TCR p-chain(Figure 3). As expected, the response 
pattern of the D10 transfectant is essentially the same as that of the D10 T cell 
clone. Somewhat more surprising is that transfectants with changes in the p- 
chain CDR1 and CDR2 also have response patterns that are nearly identical to 
D10. These data establish the validity of TCR transfection system as being 
reflective of D10 T cell clone specificity and argues against any large 
conformational change in TCR geometry by limited amino-acid mutations.
34
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Figure 3: D10 TCR transfectants have response pattern to peptide-antigen 
identical to D10 T cell clone.
The response pattern of three TCR transfectants were tested with a panel 
of variant peptides. D10:D10 is a transfectant with the wildtype D10 TCR a and 
P chains. 69.T4 is a transfectant with the D10 a-chain and a D10 p-chain with 
changes in positions 28 Asn->Asp, 29 Asn->Tyr, and 22 Asn->His. 72 is a 
transfectant with D10 a-chain and D10 p-chain with changes in position 22 Asn- 
>His, 28 Asn->Asp, 29 Asn->Tyr, 49 Gly->Ala, and 51 Gly->Ala. These 
transfectants were stimulated with 50pg/ml of peptide in the presence of B10.BR 
spleen cells. The secreted IL-2 was measured with CTLL assays.
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Some time after these experiments were completed, the error in the 
original sequence of antigenic peptide was discovered(Jeltsch, Hen et al. 1987; 
Nakagawa 1994; Yoon, S.T. et al 1994). A peptide containing arginine at 
position p2 was synthesized and compared with peptides containing either 
tryptophan or histidine at position p2 (Figure 4). It is clearly evident that D10 
responds much better to peptides containing a positively-charged residue at 
position p2, with an arginine residue being somewhat better than a histidine 
residue. Thus, HRGAIEWEGIESG (CA-wt) peptide is considered the true 
wildtype antigenic peptide. Analog peptides containing alanine substitutions of 
this wildtype peptide were synthesized and tested on the D10 transfectant 
(D10/D10). The doses required for half-maximal stimulation were determined 
(Figure 5A-E). The data for CA53 and CA63 were generated in a different 
experiment, but by comparing their titration curves to a third peptide present in 
both experiments (CA52), the doses required for equivalent stimulation were 
estimated. The stimulation capacity of all of the peptides were determined in 
reference to the wildtype peptide, CA37 (Figure 6). The pattern of response is 
similar to that established previously. The substitutions which produce the 
biggest reduction in D10/D10 stimulation are in position p2, p3, p5, p7, and p8. 
These residues as well the residue at position p4 were also identified in the 
experiments with peptides containing tryptophan at position p2. They represent 
residues that are important in either TCR or MHC interaction.
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Figure 4: D10 responds best to peptide-antigen with arginine at position p2.
Three peptides differing only in position p2 were used to stimulate the D10 
T-cell. The peptides with basic residues at position p2 stimulate much better 
than the peptide with the aromatic side chain at position p2. Squares 
(HRGAIEWEGIESG), circles (HHGAIEWEGIESG), triangles 
(HWGAIEWEGIESG).
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Figure 5: D10/D10 responses to stimulation by variant of the wild type peptides
A-D) The D10 T-cell was stimulated with varying does of peptides in order to 
determine the dose required for half-maximal stimulation.
E) The half-maximal dose required for stimulation could not be determined for 
peptides, CA53 (RGAIEWEGIESG) and CA68 (HRGAIEWEAIESG) because 
even at low doses, D10 stimulation was too high to allow measurement of 
relative concentration of peptide required for half-maximal stimulation. Thus the 
results from a separate experiment with CA53, CA68, and CA52 are reported.
40
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Figure 6: Relative Stimulation index of alanine substituted peptides
The dose required for half-maximal stimulation of D10 proliferation was 
determined for alanine substituted peptides. The relative stimulation index of 
peptides were determined by dividing the dose for half-maximal stimulation with 
the dose required for half-maximal stimulation of the wildtype peptide (CA37). 
Peptides CA53 and CA68 were first normalized with the reference peptide CA52, 
and then its relative stimulation in comparison to the wildtype peptide 
determined.
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Peptide truncation analysis with D10
Another method of determining peptide residues important for proper 
stimulation of the D10 T cell is with truncation peptides. Conalbumin peptides 
with truncations in the N-terminus or C-terminus were synthesized on the ABI 
peptide synthesizer and analyzed for stimulation of D10 transfectant (Figure 7). 
As expected from the alanine scanning substitution peptides, carboxy 
truncations can be carried out with relatively little change in D10 stimulation. Up 
to 2 amino-acids from the C-terminal can be removed without significant change. 
Removing 3 amino-acids from the C-terminal shifts the D10 stimulation dose 
response curve by less than 3 fold. Peptides with further C-terminal truncations 
would have been informative but were not synthesized. The peptides with N- 
terminal truncations have more heterogeneous characteristics. Peptide CA53, 
which has a truncation of a single residue at position p1 (histidine), stimulates 
better than the wildtype by approximately 5-10 fold. In contrast, peptide CA24 
and CA54, which have two and three N-terminal residues removed, stimulate 
worse by a factor of 1000 or more.
These truncation data identify a core region of the peptide consisting of 
residues p2 through p10 (RGAIEWEGI) which should by itself be a potent 
stimulator of D10. The residues at C-terminal positions p11, p12, and p13 do not 
seem to be very important for either MHC or TCR interactions. The first two N- 
terminal positions p1 and p2 are definitely more important. However, it is 
uncertain whether these sites are involved more in TCR interactions or MHC 
interactions.
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Figure 7: Relative stimulation index of truncated peptides
The D10 response curves to peptides were used to determine the relative 
stimulation index of truncation peptides in a manner similar to that used in Figure 
6. Interestingly, removing up to three residues from the C-terminus has little 
affect on D10 stimulation, indicating that no critical TCR or MHC binding sites are 
located in those residues. The first N-terminal residue can be removed without 
decreasing stimulation, however, removing the first and the second residues 
sharply reduces the stimulation index of the peptide.
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Identifying residues important for TCR interaction with HCW 
hybridomas
In studying TCRiligand interactions, a knowledge of the peptide residues 
involved in TCR interactions is useful. With many MHC class I molecules, the 
strong peptide binding motifs make it easier to determine the peptide residues 
which are potentially involved in TCR interaction. This sort of analysis is much 
harder for MHC class II binding peptides because of the varying lengths of MHC 
class II binding peptides and the generally weak binding motifs. Furthermore, 
peptide binding motifs were unavailable for l-Ak, although several workers were 
starting work on other alleles of l-A by eluting naturally processed peptides from 
l-A (Rudensky, Rath et al. 1991; Srinivasan, Marsh et al. 1991). Thus, an 
attempt was made to determine this information by other means for the 
antigenic conalbumin peptide.
Two different approaches were used to identify peptide residues 
potentially involved in TCR interaction. Both methods rely on differential 
responses of T-cell to peptide-antigen stimulation. In the first approach, different 
independent T-cells which can all recognize the conalbumin peptide 
HWGAIEWEGIESG were tested for differential responses to variants of that 
conalbumin peptide. This approach assumes that differences in response 
patterns of the different T cells to the panel of substituted peptides are due to 
differences in the structures of the TCRs. Amino-acid substitutions at a peptide 
residue that increases response by some T cells but decreases response by 
others would indicate TCR interaction at that residue. The reactive T-cells are 
positive controls for peptide binding to MHC and allows interpretation of non­
responding T-cells. In contrast, peptide substitutions that do not change T cell 
responses or peptide substitutions that uniformly affect response of all T cells are
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less informative. Residues positions that are not involved in discriminating T-cell 
receptors might be explained by either of two scenario’s. They may be purely 
involved in MHC binding, or they may really be involved in TCR contact but are 
not discriminated by the TCRs (i.e. TCRs are not sufficiently different to respond 
differently). The second method is to identify peptides with a single residue 
change that does not alter MHC binding affinity and yet significantly alters T-cell 
response. Peptides with substitutions induce changes in T cell responses that 
cannot be explained by differences in number of peptide:MHC complexes found 
on the APC must be involved in TCR interaction. The former approach is 
presented in this section and the latter approach is presented in the next section.
To discriminate substituted conalbumin peptides with different TCRs, it is 
necessary to generate a panel of T cells with TCRs that are as different from 
each other as possible while still recognizing the conalbumin peptide. TCRs that 
are different from D10 by only a few residues are not suitable for this purpose. 
Therefore, new T  cell hybridomas specific for conalbumin-peptide:l-Ak were 
generated. The CA1-R2W peptide (HWGAIEWEGIESG), which has tryptophan 
at position p2, was used to immunize B10.BR mice (l-Ak) and four independent 
hybridomas (HCW1.HCW2, HCW3, and HCW4) were cloned. The HCW clones 
are capable of responding to CA1-R2W given 4R spleen cell APC’s (Figure 8), 
indicating that they are restricted to the l-Ak molecule and not the l-Ek molecule.
Antibody staining was performed to characterize TCR and CD4 
expression (Figure 9). The clones all have good expression of TCR as indicated 
by staining with 2C11 and H57 antibodies, but their TCRs are distinct from D10 
and from each other as indicated by different staining with F23.1 and F23.2. The 
clones express different levels of CD4 as indicated by staining with GK1.5.
HCW2 expresses high levels of CD4, but the other clones have much lower
52
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levels CD4 expression. This, however, should not represent a significant 
problem in the analysis with these clones, because different levels of CD4s may 
change sensitivity of the TCR, but do not change the specificity of the TCR.
The HCW clones were used to probe the 23 variants (CA1-CA23) of the 
tryptophan-containing peptide which were available at the time. The response 
pattern of the HCW clones is compared to D10 transfectant in Figure 10. It is 
clear that these HCW clones have different response patterns. The most striking 
difference in T cell response pattern is induced by changes in position p2. The 
change of tryptophan to histidine strongly enhances the D10 response but 
completely ablates the response of HCW3. Given that HCW3 is an extremely 
good responder to other peptides, this lack of response to CA2-R2H and CA3- 
R2Y is very significant. Interestingly, all of the cells are insensitive to peptide 
substitutions at the C-terminal end, position p11, p12, p13. From this analysis, it 
appears that peptide positions p2, p3, p4, p5, p7 and p8 are involved in TCR 
contact and position p6 is involved in MHC binding.
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Figure 8: HCW hybridomas respond to peptides presented by 4R spleen cells
HCW hybridomas were produced by immunizing with CA1-R2H peptide. 
Spleen cells from 4R mice (200,000/well) were used to present three different 
peptides: CA1-R2W (HWGAIEWEGIESG) at 50pl/ml, CA2-R2H 
(HHGAIEWEGIESG) 0.5pl/mlt and CA8 (HWGALEWEGIESG) 50pl/ml. The 
release of IL-2 was assayed by CTLL proliferation. All of the HCW hybridomas 
respond to CA1 presented by the l-E negative 4R spleen cells indicating that 
they are i-A restricted.
54
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Figure 9: Antibody staining of TCR and CD4 on HCW hybridomas
The HCW hybridomas (1-4) were stained with antibodies to TCR and 
CD4. The D10 TCR transfectant was used as a positive control. The 




F21.1 anti-(Vb8.1 and Vp8.2)
F23.2 antiVp8.2
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Figure 10: Difference in HCW response pattern to peptides (CA1-CA23)
HCW hybridomas and the D10 TCR transfectant were stimulated with 
peptides at a single concentration (50ul/ml). The lymphoblastoid cell line CH27, 
which expresses l-Ak abundantly, was used as APCs. The secreted IL-2 was 
assayed by CTLL proliferation. Changes in the C-terminal residues of the 
peptide (p10-p13) have very little effect on T cell responses. Peptides with 
changes in position p7 (CA12-W->H and CA13-W->Y) do not allow stimulation by 
any of the T cells, suggesting that it is an MHC binding site rather than a TCR 
binding site. Changes in position p2 gives differential responses by different T 
cells that suggest TCR interaction. Other positions are equivocal because 
differential effects may be due to different overall responsiveness of the T cells.
62



















CA7 - -I - .................
CA8 -------L ---------------
CA9 -------v ............ ..
CA10 ............D ..................
CA11 ---------S -------------
CAl 2 ......H ...............
CAl 3 ..............Y ...............
CAl 4 - ............-D ----------
CAl 5 .....s............
CAl 6 ................... A -------
CAl 7 - ..............S -------
CAl 8 ......................A - - -
CAl 9 ......... V---
CA20 .......... H- -
CA21 .......... Y- -
CA22 - .........................T -
CA23 ........................... C-












The Affinity of Conalbumin Peptides to l-Ak
The difference in position p2 between the peptides CA1-R2W 
(HWGAIEWEGIESG) and CA-wt (HRGAIEWEGIESG) leads to a difference in 
D10 stimulation of at least 150 fold. Although the above experiments strongly 
suggest that this is due to a difference in TCR interaction, it was still possible that 
a difference in peptide-MHC affinity may play a significant role. Thus, it was 
important to directly measure the affinity of these peptides to l-Ak. The first 
approach attempted was to use the HEL:I-Ak specific hybridoma, 3A9, to 
measure the level of HEL:I-Ak complexes in the presence of competing 
conalbumin peptides. Unfortunately, several attempts using this method were 
unsuccessful for various technical reasons. Concurrent to this method, another 
approach was used to measure the affinity of peptide binding to l-Ak. Jeff Wilson 
at Immulogic corporation used solubilized l-Ak and competed the conalbumin 
peptides against a biotin conjugated standard peptide. Using this technique, the 
affinities of several peptides differing in position p2 were measured (Figure 11). 
Interestingly, despite the large difference in their ability to stimulate D10, CA1- 
R2W and CA-wt (CA37) have very similar affinities for l-Ak, 12pM and 13pM 
respectively (). It is clear from these measurements that differences in 
peptide:MHC affinity cannot be responsible for the differences in D10 stimulation. 
This information is very useful in the following chapter where a particular region 
of the TCR is mapped to the recognition of peptide at position p2.
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Figure 11: Peptide competition experiment used to determine apparent affinity 
of peptides
Peptides CA1-R2W(HWGAIEWEGIESG), CA2-R2H 
(HHGAIEWEGIESG), CA3-R2Y (HYGAIEWEGIESG), CA37-wt 
(HRGAIEWEGIESG), CA24 (GAIEWEGIESG), and the control peptide were 
competed against a standard biotinylated peptide for binding to soluble l-Ak 
molecules in a detergent-containing PBS solution. The MHC molecules were 
bound to plate with anti-MHC antibodies and washed. The amount of bound 
standard peptide was quantitated by adding Eu3+-Streptavidin and measuring the 
fluorescence in a fluorimeter. The affinities of CA1, CA2, and CA37 are very 
similar (10-12pM). CA3 and CA24 have somewhat lower affinities (27pM and 
87pM respectively).
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Summary
The aim of the experiments in this chapter is to better characterize the 
D10 peptide ligand. The first experiments with variants of the tryptophan- 
substituted peptides identify several residues where substitutions enhanced D10 
responses. A substitution at position p2 produces the strongest increase in 
stimulation of D10. In contrast, substitutions at the C-terminal end of the peptide 
have little effect on D10 stimulation, and substitutions at positions p3, p4, p5, p6, 
p7, and p8 produce strong decreases in D10 stimulation. These results are 
confirmed with experiments using variants of the wildtype peptides. A screening 
of peptides with the HCW hybridomas shows that there are several peptide 
positions in which amino-acid changes differentially affect hybridoma responses. 
These positions are potentially involved in TCR interaction. The most striking 
substitution involves position p2, where a tryptophan to histidine substitution 
strongly increases D10 responses but markedly reduces responses by HCW3 
indicating that the amino-acid at position is involved in TCR contact. 
Measurements of the affinity of these peptides to MHC show that they are 
relatively similar to each other in affinity for the l-Ak molecule, removing 
differences in MHC binding affinities as a possible mechanism for differential T 
cell stimulation. The other positions between p2 and p10 are tentatively 
assigned as being involved in TCR or MHC binding (Figure 12).
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Figure 12: Summary of peptide residues that affect TCR or MHC binding
The results from this chapter is summarized by this figure. The residues that 
differentially affect TCR recognition are marked with an asterisks over the residue and 
the one residue that affected all TCR responses in the same way has an asterisk below 
the residue. The last four residues, “IESG”, do not have major influence on TCR 
recognition. The second residue, which has an asterisks and a caret over it, has a very 
strong influence on TCR recognition without changing peptide:MHC affinity.
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Chapter 4
Rotational orientation of D10 TCR on MHC
Mutations in the TCR a-chain amino terminus affect recognition 
of mutations of both a and (3 chains of MHC ciass II molecules
D10 and AK8 are two independent T cell clones which recognize the 
same peptide of conalbumin (CA) presented by l-Ak, have the same TCR p- 
chain, and have similar but different a-chains. In addition, D10 recognizes 
several allogenic-MHC molecules, |-Ab,v,p,q’and d, in the absence of foreign 
peptide, whereas AK8 displays no alloreactivities. To investigate the differences 
in TCR specificity resulting from these differences in a-chains, chimeric a-chain 
cDNA’s were produced and co-transfected with the shared p-chain gene and 
CD4 gene into a TCRa'P" CD4*8‘ hybridoma, 4G4. One such TCR transfectant, 
AK8/D10, has a novel pattern of ligand specificity that is different from either that 
of D10 or AK8. The analysis of AK8/D10 and other TCR transfectants to 
determine the MHC contact sites is the focus of this chapter.
The AK8/D10 TCR differs from the D10 TCR by seven amino acids in the 
amino terminal half of the Va domain. Of these, one is in CDR1, three in the 
interval between CDR1 and CDR2, and three in CDR2 (Figure 13A). The effect 
of these sequence differences between D10 and AK8/D10 is seen most clearly 
in their different responses to CA:I-Ak, l-Ab, and l-Ad. D10 responds strongly to 
the first two and weakly to the last, while AK8/D10 responds strongly to l-Ad but 
not to the former two ligands. These new specificities of the AK8/D10 TCR are 
very intriguing because they are not present in either D10 or AK8. Since 
AK8/D10’s new TCR specificity is the result of a defined cluster of amino acid
70
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changes, it provides an excellent opportunity to map interaction sites between 
TCR and ligand.
In order to more precisely identify which part of the l-Ad molecule is most 
important in discriminating between D10 and AK8/D10, site-directed 
mutagenesis was used to produce Aa genes chimeric between Aab and Aad 
genes. These chimeric Aa genes (Figure 13B) were co-transfected into 
fibroblasts with the A|3b gene. These transfectants have interesting differences in 
their ability to stimulate D10 and AK8/D10 (Figure 14). When both HVR2 and 
HVR3 of Aab are changed to the Aad sequence, the response of the D10 TCR is 
lost, while that of AK8/D10 is gained. In contrast, when the a-chain HVR3 by 
itself is changed from Aab to Aad sequences, there is no obvious effect on the 
response of either of the TCR transfectants. These results agree very well with 
previous experiments with MHC chimeras between l-Ab and l-Ak, confirming the 
importance of HVR2 in the differential responsiveness of D10 and AK8/D10 TCR 
(Hong, Chelouche et al. 1992). Together, these data indicate that AK8/D10 will 
not respond to MHC class II ligands in which the HVR2 of Aa is of the Aab 
sequence. In contrast, the D10 TCR is not inhibited by such sequences. This 
establishes a point of discrimination between these two TCR specificities.
Finally, since HVR2 of the l-A a-chain is the main discriminator between the two 
TCR specificities, and difference between the two TCRs are in the a-chain, 
HVR2 must be interacting with TCR a-chain.
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Figure 13: Sequence descriptions of TCR and MHC a-chains.
A) The sequence difference between D10 and AK8/D10 TCRs are confined to 
seven residues in the CDR1, CDR2, and interval between CDR1 and CDR2.
B) The sequence difference between l-Ab and l-Ad in the HVR2 and HVR3 are 
shown.
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AK8/D10 -----N----- Q------ EG--------S - - S - - D - -
Position 30 36 41 48 51 54
B
Aab bbb PE FGQLAS FD PQGGLQNIAWKHNLG
Aad ddd  IL-E--------- AE-----
b2dl bdd  IL-E--------- AE-----
b2d2 bdb  IL-E-----------------
b2d3 bbd  AE-----
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Figure 14: D10/10 and AK8/D10 reactivity to l-Ab molecules with changes in the 
a-chain helix.
Approximately 100,000 D10/10 or AK8/D10 cells were stimulated with 
100,000 L-cells expressing l-Ab molecules with changes in the a-chain helix.
The allelic sequence of the three a-chain HVRs (HVR1/HVR2/HVR3) are 
represented in the figures. The secreted IL-2 was then assayed by CTLL 
proliferation.
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The other major change in AK8/D10’s specificity is its unresponsiveness 
to CA:I-Ak. AK8/D10 does not respond to peptide-antigen even at very high 
concentrations of peptide-antigen. If this unresponsiveness to peptide-antigen is 
truly absolute, it would not allow investigation of AK8/D10 responses during 
peptide specific stimulation. However, it is possible that AK8/D10 might respond 
to peptide-antigen if it is presented by a different l-A molecule. Remarkably, 
when a fibroblast cell line expressing an l-Ak molecule with the J3-chain helical 
region changed to Apb sequences was used to present peptide-antigen, strong 
conalbumin peptide specific responses could be elicited from both D10/D10 and 
AK8/D10 (Figure 15). This indicates that although the AK8/D10-TCR structure 
involved in MHC recognition is different from D10/D10, the structure responsible 
for peptide recognition is still intact. Furthermore, the difference between 
D10/D10 and AK8/D10 in requirements for MHC p-chain helix in responding to 
antigens, suggests that there is an interaction between the MHC p-chain helix 
and TCR a-chain.
Other mutant l-A molecules with different sequence changes in the p- 
chain helix can also stimulate AK8/D10 in a peptide specific manner (Figure 16). 
In this section, APC names are given with a description of its HVR sequences in 
the format kkk/kkk where each letter corresponds to the allele of origin of that 
HVR (aHVR1 aHVR2 aHVR3 / PHVR1 PHVR2 pHVR3). N27 (kkk/kdd) 
stimulates AK8/D10 very well, corroborating the importance of Ap helix in 
controlling AK8/D10’s ability to recognize peptide-antigen, first indicated by N9 
(kkk/kbb). It is also gratifying to note that the same rules apply for AK8/D10 
recognition of peptide-antigen as are seen with its response to allogeneic l-A 
molecules. Notice that AK8/D10 cannot respond to any of the l-A molecules in 
which the a-chain HVR2 has the Aab sequence, even in the presence of 
conalbumin peptide. The response to N3 (bbb/bbb) and N30 (bkb/bbb) is
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especially illuminating. The change in just the HVR2 of Aa from b to k 
sequences is sufficient to allow good stimulation of AK8/D10 with conalbumin 
peptide. In contrast, D10/D10's response to N32 (kbk/bbb) is strongly 
augmented by the presence of conalbumin peptide. These data confirm the 
importance of HVR2 of the Aa chain in controlling the differential stimulation of 
AK8/D10.
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Figure 15: D10/D10 and AK8/D10 responses to peptide-antigen presented by 
different MHC molecules
Both D 10/D 10 and AK8/D10 are capable of a strong peptide-dependent 
response when CA36 peptide (HWGAIEWEAIESG) is presented by an l-Ak 
molecule with its p-chain helix changed to the b allele sequence (N9, kkk/kbb). 
In contrast only D10/D10 can respond to peptide-antigen presented by the 
wildtype l-Ak molecule. 30,000 T cells and 20,000 APC’s were used. The 
secreted IL-2 was measured by CTLL assay.
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Figure 16: D10/D10 and AK8/D10 respond to peptide-antigen presented by 
different MHC molecules
D10/D10 and AK8/D10 have different requirements for MHC molecules in 
alloreactive responses and in peptide-antigen responses. The solid bars are T 
cell responses without addition of peptide-antigen, and the hatched bars are T 
cell responses in the presence of 50pg/ml of CA36 (HWGAIEWEAIESG). 
Approximately 50,000 T cells per well and 30,000 APCs per well were used. The 
secreted IL-2 was measured by CTLL proliferation assay.
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The fine specificity for the amino-terminal end of the antigenic 
peptide differs between two TCRs that differ in the amino 
terminal half of the Va domain
During experiments involving AK8/D10 stimulation with antigenic peptides, 
it was discovered that AK8/D10 responds better to a CA peptide with an arginine 
to tryptophan substitution at position p2, CA-R2W, than to the wildtype peptide, 
CA-wt. An experiment with four different peptides with changes in the amino- 
terminus of the peptide was earned out to investigate this further. In Figure 17, 
where AK8/D10 cell responses to N9 (kkk/kbb) APC’s and peptides are shown, it 
is clear that AK8/D10 responds best to peptides having the aromatic residue 
tryptophan at p2 (CA-R2W) or lacking the first two amino-terminal residues, but 
AK8/D10 responds weakly to CA peptides with a basic residue at position p2, 
arginine (CA-wt) or histidine (CA-R2H). It appears that a basic residue at p2 acts 
as dominant inhibitor of AK8/D10 reactivity, because removing the first two 
residues or changing the residue at position p2 to an aromatic is permissive of 
response. In contrast, D10/D10 displays a very different response pattern. Given 
the same APC’s, N9 (kkk/kbb), D10/D10 responds weakly to CA-R2W and the 
CA peptide lacking p1 and p2 but responds well to CA-wt and CA-R2H. This is a 
clear reversal in the rank order of responsiveness to peptides in comparison to 
AK8/D10. Differences in peptide affinity for the different MHC molecules cannot 
account for the reversal in peptide rank order between AK8/D10 and D10/D10, 
because a change in affinity would increase or decrease stimulation of both T 
cells. Therefore, this reciprocal gain/loss pattern produced by changes in 
position p2 of the peptide strongly suggests that the residue at position p2 
makes contact with the part of the TCR that differs between AK8/D10 and 
D10/D10, namely CDR1 and/or CDR2 of the a-chain.
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Figure 17: D10/D10 and AK8/D10 have different specificities for antigenic- 
peptide
The response pattern of D10/D10 and AK8/D10 are compared. D10/D10 
responds best to CA37-wt and CA2-R2H. AK8/D10 responds best to CA1-R2W  
and CA24 (truncation of the 2 N-terminal residues). The T-cells were stimulated 
with peptides and either N6 (kkk/kkk) or N9 (kkk/kbb) cells. The secreted IL-2 
was measured by CTLL proliferation.
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CDR2 of TCR a,-chain maps to the amino-terminus o f peptide- 
antigen
In order to refine TCRiligand interaction contact sites to a smaller surface 
area, it was necessary to use TCR mutants with more limited changes in the 
CDR loops. For this, D10 a-chain cDNAs encoding single amino acid changes 
were made. These single amino-acid changes are all a subset of the differences 
between D10/D10 and AK8/D10. Single amino-acid sequence changes allow for 
the best resolution of interaction site on the TCR and decrease the possibility of 
conformational distortion away from the site of mutation. Although a single 
amino-acid change may not recover the full change in phenotype between 
D10/D10 and AK8/D10, it would identify any dominant interaction site between 
TCR and ligand. The sequences of variant a-chain which have been transfected 
are shown in Figure 18.
The a-chain cDNA’s encoding single amino-acid changes were co­
transfected with D10 p-chain gene and the CD4 gene into 4G4 cells. The 
surface expression of TCR and CD8 molecules are shown in (Figure 19). The 
response patterns of the resulting transfectants were then compared to 
D10/D10’s response pattern to CA:I-Ak, l-Ab, and l-Ad (Figure 20). Surprisingly, 
most of the single amino-acid mutation transfectants responded in a pattern 
nearly indistinguishable from D10/D10. They responded best to CA:I-Ak, then I- 
Ab, and worst to l-Ad.
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Figure 18: The amino-acid sequences of the mutated TCR a-chain polypeptides
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a-Chain Sequences of TCR Transfectants With a-Chain Mutations
CDR1 CDR2 CDR3
30 36 41 48 51 54 97
D10 EPSTFDYFPWYROFPGKSPALLIAISLVSNKK-..IYFCA ATGSFNKLTFGAGTRLAVCPY IQNPE
AK8  N-----Q----EG.....S--S--D--...-----**PNYT-SS--T-----Q-S-N-----
AK8/D10  N---- Q----EG-----S--S--D--...----------------------------------
AK8/D10-S51L  N.... Q----EG-----S-----D-~...------------- -------------- ------
D30N  N-------------------------- ...----------------------------------
K41E--------------------  E--------------- ...----------------------------------
S42G  G-------------- ...----------------------------------
A48S ------------------------------------------ s -------------- . . . --------- ----------------------------------------- -----------
L51S ------------------------------------------------ s  . . . --------------------------------------------------------------
N54D  D--...----------------------------------
K97D  . . . - .................... D ----------- -----------------
K97E  . . . ------------------  E --------------------------------
Figure 19A: F23.2 (anti-Vp8.2) staining of TCR transfectants
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F23.2 (anti-Vp8.2)
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Figure 19B: 3D3 (anti-D10 TCR) staining of TCR transfectants
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Figure 19C: 5A (anti-D10 TCR) staining of TCR transfectants












Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
5A (anti-D10 TCR)
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Figure 19D: 10B (anti-D10 TCR) staining of TCR transfectants
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10B (anti-D10 TCR)
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GK1.5 (anti-CD4)
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Figure 19F: GK1.5 (anti-CD4) staining ofTCRtransfectants
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Figure 19G: YAe (anti-Eab:l-Ab) staining of TCR transfectants
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YAe (anti-Ea-Peptide:l-Ab)
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Figure 20: Responses of TCR transfectants to l-Ab, l-Ad, and I-Ak + antigen
30,000 T cells per well were stimulated with varying numbers of APCs. 
Spleen cells from C57BL6/J (b), BALB.c (d), and B10.BR (k) were used. For 
stimulation with l-Ak APCs, 50pg/ml of CA37 (HRGAIEWEGIESG) was also 
included. The secreted IL-2 was quantitated by CTLL proliferation assay.
A) Responses of D10/D10, D30N, K41E, and S42G are shown.
B) Responses of AK8/D10, A48S, L51S, and N54D are shown.
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Despite their similarity in pattern, quantitative differences do exist between 
the transfectants. The transfectant with a mutation in CDR1 (D30N) has an 
enhanced response to l-Ad in comparison to D10/D10’s response to l-Ad, while 
its responses to l-Ab and l-Ak+conalbumin-peptide (CAP) are nearly identical to 
D10’s response. A more prominent difference is seen with the transfectant 
L51S, which has a Leu to Ser change in the a-chain CDR2 position 51. This 
transfectant responds to l-Ab even better than does D10/D10, but its response to 
CA:I-Ak is significantly blunted in comparison to D10’s response. Furthermore, 
its response to CA:I-Ak is reduced in comparison to its own response to l-Ab.
The difference in specificity of L51S TCR for peptide as compared to 
D10/D10 is apparent in Figure 21, where four different peptides differing in only 
position p2 were used to stimulate the transfectants. While L51S responds well 
to the wildtype CA peptide (CA-wt), it does not respond to CA-R2W or CA-R2Y, 
and its response to CA-R2H is diminished by approximately 1.5 log shift. In 
contrast, the response patterns of the other single amino-acid mutation 
transfectants’ are not distinguishable from those of D10.
Since CA-R2W is a relatively poor stimulator of D10/D10, it was desirable 
to demonstrate L51 S’s specific loss of reactivity to CA-R2W in a context where 
D10/D10 responded to CA-R2W as well as to the wildtype peptide. Fortuitously, 
this was possible with the lymphoblastoid cell line, TF, which carries an l-Ak 
molecule with changes near the a-chain HVR2 that make it a very good 
presenter of CA-R2W. Given TF APCs, CA-R2W and CA-wt both stimulate 
D10/D10 very well, producing response curves that are nearly superimposible
■A
(Figure 22). In contrast, L51S responds strongly to CA-wt but still does not 
respond to CA-R2W. Since the change in position p2 of the peptide-antigen 
ablates only the L51S response without affecting the D10/D10 response, there 
must be an interaction between TCR a-chain residue 51 and peptide position p2.
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Figure 21: Responses of TCR transfectants to peptides with substitutions at 
position p2
TCR transfectants (~30,000/well) were stimulated with varying 
concentrations of peptide (3 fold dilutions) in the presence of B10.BR spleen 
cells (300,000/well). The secreted IL-2 of the culture supernatant was 





A) Responses of two independently produced D10/D10 clones (A2 and A1B6), 
D30N, and K41E are shown.
B) Responses of S42G, A48S, L51S, and N54D are shown.
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Figure 22: D10/D10 and L51S responses to peptides with substitutions at p2 
given the TF APC
D10 and L51S TCR transfectants (50,000/well) were stimulated with three 
peptides with substitutions in position p2; CA1-H2W (HWGAIEWEGIESG), CA2- 
R2H (HHGAIEWEGIESG), and CA37-wt (HRGAIEWEGIESG). The TF APC 
(50,000/well) expresses l-A molecules identical to l-Ak except for a-chain 
positions 44, 48, 53, 56, and 57 (Buerstedde, J. M. et al. 1988). The secreted IL- 
2 was quantitated by CTLL assay.
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Model of the ternary structure o f TCR and MHC
In building a model of interaction between TCR and MHC, four 
independent constraints on TCR interaction with respect to peptide and MHC 
were considered. First, a portion of the CDR1 and CDR2 of the TCR a-chain 
must be in contact with the HVR2 of MHC a-chain. This is indicated by the 
experiment with mutant l-A molecules with Aa b/d shuffles and previous data 
with b/k shuffles (Hong, Chelouche et al. 1992). Second, a portion of the TCR a- 
chain CDR1 and CDR2 must be in contact with the MHC p-chain HVR3. This is 
indicated by experiments with the with the conalbumin-specific response of 
AK8/D10 and D10/D10. Third, TCR a-chain CDR1 and/or CDR2 must interact 
with the N-terminus of the peptide. This follows from the preferential response of 
D10/D10 and AK8/D10 for basic residues and aromatic residues, respectively, at 
position p2 of the peptide. Finally, TCR a-chain residue 51 (CDR2) must be in 
proximity with peptide position p2, as indicated by experiments with transfectant 
L51S.
Using these four constraints, a three-dimensional model was developed 
on a computer using the MIDAS program. The l-Ak molecule is modeled by the 
human class II MHC molecule, HLA-DR1 (Brown, Jardetzky et al. 1993). The 
D10 TCR molecule is modeled by a mouse antibody (Suh, Bhat et al. 1986). In 
Figure 23 the a-carbon backbone of models of MHC and TCR are depicted in 
several points of view. TCR CDRs are highlighted with colored space filling 
representations. The TCR model has its a-chain placed over both helices of 
MHC chains and over the N-terminus of the peptide. Then the TCR and MHC 
models were positioned as close to each other as possible without overlapping.
It is interesting to note that the antigen binding surface of TCR, represented by 
the space-filling diagrams of CDRs, is roughly rectangular in shape and that the
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orientation presented here aligns with the peptide binding groove. Naturally 
processed peptides are in the extended conformation in the peptide-binding 
groove and extend out of the groove in MHC class II molecules. The orientation 
of the long axis of the TCR antigen-binding surface with the peptide allows the 
greatest contact surface with peptide. As was discussed in the introduction, it is 
not possible to produce a model with very high detail because of the 
uncertainties of regarding the TCR and MHC structures. Nevertheless, a model 
of the scale presented here is useful in making predictions about TCR.Iigand 
binding sites and in explaining pre-existing data
113
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Figure 23: A model of TCRrMHC orientation
TCR a-chain CDR1 green, CDR2 red, CDR3 magenta.
TCR p-chain CDR1 cyan, CDR2 blue, CDR3 yellow.
A) The point of view is looking through TCR down on to MHC helices. MHC 
chain is to the top.
B) The point of view is looking down the axis of the peptide binding groove. 
MHC a-chain is to the left.
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This model, which is based on TCR aCDR1 and aCDR2 mutations, 
makes several predictions about other TCR MHC interaction locations. It 
predicts that aCDR3 makes contact with both peptide and MHC a-chain helix. 
The most distal tip (from the framework residues) of the a-chain CDR3 would be 
more involved in MHC contact and the more proximal part of the loop would be 
involved in peptide contact. Evidence exists to support this prediction. 
Jorgensen and co-workers reported that aCDR3 contact residues with peptide 
are found in the N region, which is closer to the framework and away from the 
distal tip of the CDR loop. In the D10 system, a TCR transfectant (D10a-K97E) 
with a mutation in the distal tip of aCDR3 (position 97 Lys->Glu) also provides 
data consistent with this prediction. K97E responds very well to peptide-antigen 
but no longer responds to l-Ab or l-Ad (Figure 24). This is the converse of the 
response pattern of L51S, which has a decrease in peptide response but no 
change in the allo-response, and can be interpreted to mean that position 97 in 
a-chain is important for MHC helix binding rather than peptide binding. Another 
TCR transfectant with a similar but distinct change in position 97 has a very 
different pattern of response. This transfectant, K97D, has a Lys to Asp 
substitution at position 97 and this is very similar to D10a-K97E. However, 
D10a-K97D maintains its reactivities to allogeneic-MHC molecules and has a 
response pattern very similar to D10. The subtle nature of the difference 
between the two CDR3 mutations which result in such a distinct difference in 
response pattern to antigens is remarkable and highlights the importance of 
CDR3 loops in TCR specificity.
This model of TCR:ligand interaction presented here also makes 
predictions about where TCR p-chain CDRs would bind peptide:MHC. TCR 
pCDR3 would be in proximity with MHC p-chain helix as well as peptide. TCR 
PCDR2 would be in proximity to the C-terminal of peptide. TCR PCDR1 would
116
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be in proximity with MHC p-chain helix. Tests of these predictions would provide 
the strongest validation of this model. Several approaches to perform such tests 
are discussed in the discussion section, but tests of TCR p-chain are beyond the 
scope of this thesis.
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Figure 24: The effect of CDR3 changes in D10 TCR a-chain
K97E and K97D are TCR transfectants with a single amino-acid mutation 
in a-chain CDR3 position 97. The response pattern of D10/D10, K97E, and 
K97D to l-Ab, l-Ad, and l-Ak + antigen (CA37-wt) were compared. 30,000 T cells 
per well were stimulated with varying numbers of APCs. Spleen cells from 
C57BL6/J (b), balb.c (d), and B10.BR (k) were used. For stimulation with l-Ak 
APCs, 50pg/ml of CA37 (HRGAIEWEGIESG) was also included. The secreted 
IL-2 was quantiated by CTLL proliferation assay.
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A major goal of this thesis is to position spatially the D10 TCR over its 
peptideiMHC ligand. The data presented here complement the previous study 
with D10 a-chain performed in this laboratory. In that study, allogeneic MHC 
ligands were used to map TCR a-chain CDR1 and CDR2 to MHC a-chain HVR2. 
This thesis confirms the previous finding using allelic shuffles between b and d 
(instead of b and k) to discriminate AK8/D10 and D10/D10. This also proves that 
the critical differences between l-Ab and l-Ad in stimulating D10/D10 and 
AK8/D10 lie within the aHVR2 area. However, since the peptide-antigen in 
these allogeneic MHC molecules is undefined, there remains the possibility that 
an altered MHC peptide binding repertoire is confounding the interpretation of 
the data. Thus, the studies in this thesis have examined similar interactions 
between TCR and MHC during stimulation by a specific peptideiMHC complex.
By using MHC molecules different from the wildtype l-Ak, peptide specific 
responses can be evoked from T cells with the AK8/D10 TCR. The finding that 
changing the TCR a-chain CDR1 and CDR2 dramatically changes the MHC 
specificity while still allowing for peptide recognition suggests a certain degree of 
separation between MHC recognition and peptide recognition. This is consistent 
with previous proposal of TCR and peptideiMHC interaction which attributed 
peptide recognition largely to the a  and p chain CDR3s of the TCR (Chothia, 
Boswell etal. 1988; Davis and Bjorkman 1988; Claverie, Prochnicka-Chalufour 
etal. 1989)
120
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Defining TCR:ligand Contact Site During Peptide Specific 
Recognition
The establishment of peptide-specific stimulation of AK8/D10 as well as 
allogenic stimulation has allowed the comparison of MHC requirements of 
D10/D10 and AK8/D10 in responding to both stimuli. Interestingly, AK8/D10 and 
D10/D10 are similarly affected by changes in the presenting MHC class II 
molecule for response to peptide and for responses to allogenic MHC. The MHC 
a-chain HVR2 controls the differential stimulation of AK8/D10 and D10/D10.
This supports the idea that TCRs bind MHC much in the same way during 
peptide dependent recognition as it does during recognition of allogeneic MHC 
molecules. This in turn predicts that alloreactive responses will be affected by 
peptide bound to the allogenic MHC molecule. Consistent with this, several 
studies have demonstrated the importance of peptide bound to allogeneic MHC 
molecules during such responses(Rotzschke, Falk e ta l. 1991; Sherman and 
Chattopadhyay 1993).
Examination of peptide specific responses has allowed identification of 
other TCR:ligand interactions sites. Although AK8/D10 can respond to peptide- 
antigen, its specificity to peptide is clearly different. AK8/D10 responses are 
weaker to the peptides that stimulate D10/D10 well (those containing basic 
residues in position p2) and stronger to peptides that stimulate D10/D10 poorly 
(peptides with aromatic residues in position p2). These gain and loss of 
reactivities are powerful evidence for a direct interaction between residues in 
CDR1 and CDR2 of the TCR a-chain with the N-terminal residues of the peptide. 
More precise mapping supporting a TCR a-chain CDR2 interactions with peptide 
comes from a TCR transfectant with a single amino-acid change in position 51 of 
the CDR2 of the TCR a-chain. This transfectant has a change in reactivity that
121
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maps to position p2 of the peptide. Although previous studies have implicated 
CDR1 and CDR2 in peptide contact, they mostly consisted of loss of recognition 
mutations or correlations between sequence and specificity. Thus the 
determination of contact sites with AK8/D10 and L51S in peptides specific 
responses in this thesis represents the most accurate localization of such 
reactivities to date.
A New Model for the Rotational Orientation of the TCR:ligand 
Complex
These new data have been used to generate a model of TCRrMHC 
interaction that is significantly different from that proposed by other workers. 
Claverie, Davis, and Chothia had proposed that the germline encoded CDR1 and 
CDR2 loops of TCR are mainly responsible for MHC binding and the somatically 
encoded CDR3 loops are mainly responsible for peptide binding. Very little is 
said about the role of germline encoded CDRs in peptide specificity. The data 
produced in this thesis clearly argues for a significant role in peptide specificity at 
least for CDR2. Jorgensen et al. proposed a model in which TCR a-chain 
interacts mostly with MHC (3-chain, and TCR p-chain interacts with MHC a-chain. 
The data in this thesis suggests a different model, that TCR a-chain and p-chain 
make contact with MHC helices of both chains with the TCR a-chain towards the 
N-terminal half of the MHC-bound peptide. In considering the differences 
between the model proposed here and the previous models, the basis of the 
previous models must be considered. The earliest models by Claverie, Davis, 
and Chothia were based on the newly determined structure of an MHC class I 
molecule and on comparative sequence analysis of TCR and antibodies. While 
these models provided a useful intellectual framework, they did not address the 
issue of rotational orientation between MHC and TCR. The model proposed by
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Jorgensen et al. is based on correlations between CDR3 residues in both the a 
and p chains of the TCR with amino acid residues lying close together near the 
center of the peptide. This positions the two CDR3 loops over the center of the 
antigenic peptide, but such correlations between two points near the rotational 
axis of the receptor have little power in resolving the rotational orientation. 
Furthermore, since the CDR3 of antibodies and presumably of TCRs are the 
most variable in sequence and structure, it is even more difficult to assign a 
rotational orientation of the TCR from such data. The model proposed in this 
thesis consists of correlations between the more peripherally located CDR2 and 
the N-terminus of the peptide, and between CDR1/CDR2 and the MHC helices. 
Thus, these data have more power in determining the rotational orientation of 
TCR on MHC.
Recently, SEB has been shown to bind to the a-chain helix of the MHC 
class II molecule (Jardetzky, Brown et al. 1994). This indicates that during 
SEB:MHC binding, the TCR p-chain must be in some proximity to the MHC a- 
chain helix. Although TCR:MHC orientation may not be the same during peptide 
mediated versus SEB mediated binding, there is some evidence to suggest that 
the TCR interacts directly with the MHC a-helical regions during responses to 
SEB. The model proposed in this thesis places TCR p-chain over both MHC a- 
heiices. This could allow for SEB interaction with the TCR p-chain without 
having to change rotational orientation. Furthermore, other superantigens which 
might bind to p-chain of the MHC molecule, such as SEA and SEB (Karp and 
Long 1992), would also be able to interact with TCR p-chain without having to 
postulate different rotational orientations for each superantigen and peptide. On 
the other hand, while it is elegant to propose a similar rotational orientation in 
TCR:peptide-MHC and TCR:superantigen-MHC interactions, this does not
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necessarily have any consequences regarding consistency of rotational 
orientation within each class of interaction.
A single rotational orientation for TCR on peptide:MHC
The proposal of a rotational orientation between a particular TCR and its 
MHC ligands raises the question whether there is only one rotational orientation 
for all ap-TCRs bound to peptideiMHC complexes. The fact that antibodies bind 
antigen in many different orientations and epitopes makes this question more 
important. Although this question must be eventually answered by more 
definitive experiments, there are reasons to suggest that TCRs bind MHC 
molecules in a fixed orientation. Antibody-antigen binding is different from TCR- - 
antigen binding. Even antibodies that bind MHC molecules seem very different 
in comparison to the way TCR bind MHC.. Antibodies bind antigen with very 
high affinities. They bind many different epitopes and are usually not dependent 
on a specific peptide for good binding. Interestingly recent data with yS-TCRs 
show that these TCR share with antibodies the ability to bind different epitopes 
and being independent of peptide bound to the binding groove of MHC. In 
contrast ap-TCRs bind ligand with lower affinity (Matsui, Boniface et a l.; Weber, 
Traunecker et a l.; Sykulev, Brunmark et al. 1994) and bind the peptide and MHC 
simultaneously. ap-TCRs are very sensitive to the specific peptide bound to 
MHC. This must be a reflection of the different functional requirements of the 
molecules. On the mature T cell, TCRs must recognize foreign peptide bound to 
self-MHC molecules. On the developing thymocyte, TCRs must bind MHC in a 
manner compatible with both positive and negative selection.
A consideration of the structures of MHC and TCR co-receptor molecules 
also suggests a fixed orientation between TCR and MHC molecules. Despite the
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allelic polymorphisms in MHC and the large diversity of bound peptide 
complexed with MHC molecules, the MHC molecules have very similar domain 
organization and overall three-dimensional structure that could limit the TCR 
structures that can interact with MHC in a functionally meaningful manner. 
Furthermore, MHC molecules are asymmetric molecules that would further 
reduce the degrees of freedom in TCR structure and manner of binding to the 
MHC ligand. After TCR binding to peptideiMHC ligands, the appropriate co- 
receptor molecule, CD4 or CD8, is needed by the T cell for optimal signaling. 
During the formation of a molecular complex of the TCR with peptideiMHC, the 
co-receptor must bind simultaneously to the non-polymorphic co-receptor binding 
region of the MHC molecule. This close proximity of the co-receptor to the TCR 
during TCRiligand binding suggests that the TCR and the co-receptor molecules 
may also bind to each other. This is further supported by the finding that certain 
clonotypic anti-TCR monoclonal antibodies, and even their non-stimulating Fab 
fragments, induce a physical association of CD4 with the TCR (Yoon et al.,
1994). Moreover, certain anti-TCR monoclonal antibodies, including anti-Va, are 
antagonized by Fab fragments of anti-CD4, suggesting that this interaction is 
with the TCR a-chain (Yoon et al., 1994). At the very least, TCR and co-receptor 
molecule structures and their binding sites on the MHC molecule must be 
compatible with simultaneous binding on the MHC molecule. Interestingly, a 
motif in TCR a-chain sequences has been found that correlates highly with the 
usage of the CD4 co-receptor and with MHC class II recognition (Medzitov 
1994). This suggests that there might be a CD4 binding or accommodation site 
on the TCR. If this correlation found in this retrospective study of sequences is 
confirmed by a prospective study of specific mutants, it could provide the 
strongest evidence for a fixed orientation in TCR binding to peptideiMHC.
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Implications of Va CDR2 binding to the N-terminus o f the 
antigenic peptide
The results In this study support a Va CDR2 Interaction with the N- 
terminus of peptides and a CDR1 interaction with MHC. If this orientation 
between TCR and ligand is general, then it predicts that certain Va gene 
segments in TCR molecules will be correlated with specificity for certain 
peptideiMHC combinations. An example of this sort of correlation is found in 
TCRs specific for cytochrome-c (cyt-c) peptides bound to l-E. The high 
correlation between Va11 and recognition of cyc-t:l-E is consistent with the 
results in this study in two ways. First the correlation between the usage of 
Va11 and the non-polymorphic l-E a-chains suggests an interaction between 
these two polypeptides. Second, since the high bias towards V a11 usage is 
observed in response to cyt-c peptide, the V a11 germline-encoded sequences 
must be important in binding residues on the peptide.
A good way of testing the model proposed in this thesis and of 
demonstrating its generality is to use a mouse transgenic for the p-chain of a 
TCR specific for a known peptide. T  cells from an animal transgenic for the p- 
chain of the TCR will probably display a preference for using a particular Va 
gene segment when immunized with the specific peptide. Changes in peptide 
residues closer to the C-terminus are predicted to have much weaker effects on 
Va usage. In mice expressing only a single a-chain the converse situation is 
predicted: Vp usage will be more strongly correlated with changes in the peptide 
at more C-terminal positions. Interestingly, an experiment very similar to this 
proposal has been performed already (Jorgensen, Reay et a l.). That study used
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peptide substitutions that are very near the center of the peptide and thus CDR3 
correlations were sought and found, as opposed to the above proposal which 
would use peptide changes closer to the ends of the peptide. It is interesting, 
however, to note that changes in the more N-terminal residue of the peptide 
(residue 99) were correlated to changes in the TCR a-chain, and changes in the 
more C-terminal residue of the peptide (residue 102) were correlated with 
changes in the p-chain. Furthermore, a-chain transgenic mice had shifts in Vp 
gene segment usage depending on different amino-acids at position 102 (more 
C-terminal). This result is similar to what is predicted by the model proposed in 
this thesis. Recently single-chain D10 TCR transgenic mice have been 
produced. These mice are very good candidates for performing immunization 
experiments with CA1-R2H and CA37-wt peptides to determine whether 
changes in the terminal region of the peptide will influence V  gene usage more 
than CDR3 sequence motifs.
An intriguing question raised by the model proposed in this thesis is what, 
if any, purpose does CDR2 interactions with peptide provide for the T cell. One 
possibility is that this form of interaction provides a mechanism for germline 
encoding of TCR specificity for peptides as well as for MHC. Such a mechanism 
may be used to produce TCRs with a high likelihood of recognizing a particular 
peptide-antigen. This may be useful in fighting infection against a common 
microbe or may be useful in thymic selection where a bias for or against certain 
peptides may be useful. On the other hand, this orientation of TCR to ligand 
may merely reflect the phylogenetic heritage of the TCR:MHC system. Perhaps 
the primordial receptor molecule, that gave rise to the a(3-TCR, bound MHC 
molecules (or its equivalents) by straddling both helices with each of its dimeric 
polypeptides. In this situation, the interaction of CDR1s and CDR2s with peptide
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residues may not be advantageous to the T  cell system and may instead 
as a limitation to the generation of TCR repertoire diversity.
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